Does genotype predict response to treatment in children infected with hepatitis B perinatally?

Journal of Medical Virology

Volumn 84, Issue 10, 2012, Pages 1535-1540

  Boxall, Elizabeth ^a,b   Sira, Jaswant ^b   Kaskar, Shamima ^a   Workman, Judith ^a   Kelly, Deirdre ^b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antivirals; Children; HBV genotypes; Hepatitis B virus; Treatment response

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PREDNISOLONE;

ADOLESCENT; ADULT; AFRICAN CARIBBEAN; ARTICLE; ASSAY; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DIAGNOSTIC KIT; EUROPE; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PERINATAL INFECTION; PREDICTION; PRESCHOOL CHILD; SCHOOL CHILD; SEROCONVERSION; TREATMENT RESPONSE;

ADENINE; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DNA, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERONS; LAMIVUDINE; ORGANOPHOSPHONATES; PREDNISOLONE; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 84865531296     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23308     Document Type: Article

References (31)

1. Boxall EH, Harrison TJ, Wheeley SM. 1990. HBV-DNA levels in hepatitis B carrier mothers: Relationship with protection against perinatal transmission by vaccine. In: Blaine-Hollinger F, Lemon Stanley M, Margolis Harold S, editors. Viral hepatitis and liver disease. Houston, USA: Williams & Wilkins. pp 757-759.
2. Boxall EH, Sira J, Standish RA, Davies P, Sleight E, Dhillon AP, Scheuer PJ, Kelly DA. 2004. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed 89:F456-F460.
3. Boxall EH, Sira J, Ballard AL, Standish RA, Davies P, Dhillon AP, Scheuer PJ, Kelly DA. 2006. Long term follow up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol 78:888-895.
4. Chu CJ, Hussain M, Lok AS. 2002a. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 123:1756-1762.
5. Chu CJ, Hussain M, Lok AS. 2002b. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36:1425-1430.
6. Cooksley WGE. 2010. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat 17:601-610.
7. Derso A, Boxall EH, Tarlow MJ, Flewett TH. 1978. Transmission of HBsAg from mother to infant in four ethnic groups. Br Med J 1:949-952.
8. Enomoto M, Tamori A, Nishiguchi S. 2006. Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab 52:43-47.
9. Erhart A, Blondin D, Hauck K. 2005. Response to interferon alpha is hepatitis B genotype dependent: Genotype A is more sensitive to interferon than genotype D. Gut 54:1009-1013.
10. Fung SK, Lok ASF. 2004. Hepatitis B genotypes: Do they play a role in the outcome of HBV infection? Hepatology 40:790-792.
11. Gregorio M, Jara P, Hierro L, Diaz C, De La Vega A, Vengnente A, Iorio R, Bortolotti F, Crivellardo C, Zancan L, Daniels H, Portman B, Mieli-Vergani G. 1996. Lymphobastoid interferon alpha with or without steroid pre-treatment in children with chronic hepatitis B: A multicentre controlled trial. Hepatology 23:700-707.
12. Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK, Schalm SW, Naoumov NV. 2007. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 79:1055-1063.
13. Jonas MM, Kelly D, Pollack H, Mizerski J, Sorbel J, Frederick D, Mondou E, Rousseau F, Sokal E. 2008. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 47:1863-1871.
14. Kao J-H, Wu N-H, Hussain M, Lok AS. 2000. HBV genotype B is associated with better response to interferon therapy than genotype C. J Hepatol 33:998-1002.
15. Keefe EB, Marcellin P. 2007. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol 5:285-294.
16. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, Negus SE, McMahon BJ. 2007. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 133:1452-1457.
17. Marcellin P, Piratvisuth T, Brunetto M. 2009. HBsAg clearance continues to increase after end of treatment with Pegasys±lamivudine: 5 year follow up study. Hepatol Int 3:108.
18. NICE Guidance: TA96 Hepatitis B (chronic)-adefovir dipivoxil and pegylated interferon alpha-2a: Guidance 23 February 2006.
19. Palumbo E. 2007. Hepatitis B genotypes and response to antiviral therapy: A review. Am J Ther 14:306-309.
20. Price N, Boxall EH. 2007. Treatment of children persistently infected with hepatitis B virus: Seroconversion or suppression. J Antimicrob Chemother 60:1189-1192.
21. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. 2002. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 123:1848-1856.
22. Shiffman M, Marcellin P, Jeffers L. 2004. HBsAg seroconversion in adefovir dipivoxil (ADV) chronic hepatitis B (CHB) patients. J Hepatology 40:17.
23. Sokal EM, Conjeevaram H, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J. 1998. Interferon alpha for treatment of paediatric chronic hepatitis B: A randomised controlled multi-center trial. Gastroenterology 114:988-995.
24. Sokal EM, Roberts EA, Mieli-Vergani G, McPhillips P, Johnson M, Barber J, Dallow N, Boxall E, Kelly D. 2000. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 44:590-597.
25. Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Vegnente A, Little NR, Gardener SD, Jonas MM. 2006. Long term lamivudine therapy for children with HBeAg positive chronic hepatitis B. Hepatology 43:225-232.
26. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. 2000. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness J Gen Virol 81:67-74.
27. Thomas HC. 2007. Best practice in the treatment of chronic hepatitis B: A summary of the European viral hepatitis Educational Initiative (EVHEI). J Hepatol 47:588-597.
28. Weigland J, Hasenclever D, Tillman HL. 2008. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from explorative analysis of published. Therapy 3:211-220.
29. Wheeley SM, Boxall EH, Tarlow MJ. 1987. Prognosis of children who are carriers of hepatitis B. Br Med J 294:211-213.
30. Wheeley SM, Tarlow MJ, Boxall EH. 1989. Chronic hepatitis B in male and female children of HBsAg carrier mothers. J Hepatol 8:226-231.
31. Wheeley SM, Jackson PT, Boxall EH, Tarlow MJ, Gatrad AR, Anderson J, Bissenden J. 1991. Prevention of perinatal transmission of hepatitis B virus (HBV): A comparison of two prophylactic schedules. J Med Virol 35:212-215.